Aptose Bioscienc Stock Price, News & Analysis

Aptose Biosciences has initiated the APTIVATE Phase 1/2 trial for tuspetinib, a mutation-agnostic TKI for relapsed or refractory acute myeloid leukemia (R/R AML). The trial starts with a 120 mg monotherapy dosing, following another clinical response from a patient on 40 mg. Tuspetinib has demonstrated complete remissions across various dose levels and mutational profiles with a favorable safety profile, avoiding severe toxicities seen with competitors. The trial aims to enrich specific patient populations, including those with TP53 and FLT3 mutations, as backed by FDA fast-track designation.

Aptose Biosciences announced that its Chairman and CEO, William G. Rice, Ph.D., will present at the Biotech Showcase™ 2023 Conference on January 10, 2023, at 10:00 a.m. PST in San Francisco. The company specializes in developing oral kinase inhibitors for hematologic malignancies, with two clinical-stage products: tuspetinib for acute myeloid leukemia and luxeptinib for other hematologic conditions. Additionally, Aptose will hold meetings at the LifeSci Advisors Corporate Access Event from January 9-11, 2023. The presentation will be available via webcast on the company’s website.

Aptose Biosciences announced an equity distribution agreement with JonesTrading to sell common shares through at-the-market offerings on NASDAQ. The company can issue shares worth up to US$50 million as outlined in a prospectus filed with the SEC. Aptose focuses on developing oral kinase inhibitors for hematologic malignancies, with two candidates, tuspetinib and luxeptinib, currently in clinical trials. This strategic move may enhance capital for ongoing research and operations.

Aptose Biosciences has released a clinical update on tuspetinib, a myeloid kinase inhibitor, showing promising results in a Phase 1/2 trial for patients with relapsed/refractory acute myeloid leukemia (AML). As of October 6, 2022, 60 patients have been treated with doses ranging from 20 mg to 200 mg, achieving multiple complete remissions (CR). Tuspetinib's favorable safety profile and high response rates suggest potential for combination therapies. Additionally, luxeptinib continues to show efficacy in hematologic malignancies, with ongoing trials for modified formulations.

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) will present key updates at the ASH Annual Meeting on December 11, 2022. The webcast at 10:00 AM EST will cover clinical data for tuspetinib and luxeptinib. Tuspetinib, a myeloid kinase inhibitor, is in a Phase 1/2 trial for acute myeloid leukemia (AML). Key poster presentations include data on the Phase 1/2 dose escalation study of tuspetinib and luxeptinib. Additional data will be shared at the event, providing insights into the company’s advancements in oncology.

Aptose Biosciences has initiated dosing for the first patient in a continuous dosing regimen of the G3 formulation of luxeptinib for relapsed or refractory acute myeloid leukemia (AML). This Phase 1a/b clinical trial seeks to enhance drug bioavailability significantly, as the new formulation is expected to provide similar plasma exposure to the higher dose of the original formulation while reducing potential toxicity. The company is optimistic about the G3's efficacy and hopes it will yield better clinical responses in difficult-to-treat AML patients.

Aptose Biosciences Inc. (NASDAQ: APTO) announced the acceptance of clinical data for tuspetinib and luxeptinib for poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting from December 10-13, 2022, in New Orleans, LA. The studies include a Phase 1/2 trial for tuspetinib in patients with relapsed or refractory acute myeloid leukemia and a Phase 1a/b trial for luxeptinib targeting similar patient groups. Furthermore, a clinical update webcast will be held during the ASH meeting.

Aptose Biosciences announced the completion of its Phase 1/2 trial for tuspetinib (HM43239), demonstrating a superior safety profile and clinical responses, including complete remissions in challenging r/r AML patients. The company reported a net loss of $9.8 million for Q3 2022, an improvement from $11.3 million in Q3 2021. Total cash as of September 30, 2022, was $55.4 million. Recruitment for an expansion trial will target enriched patient populations, with continuous dosing of the new luxeptinib G3 formulation commencing soon.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced it will release its financial results for the quarter ending September 30, 2022, on November 1, 2022, after market close. The company will also provide a corporate update during a conference call scheduled for 5:00 PM ET that same day. This call can be accessed via an audio webcast, and a replay will be available for 30 days on the company's website. Relevant documents will be available on SEDAR and EDGAR.